ArticlePloS one
Blindness and visual impairment in Central Europe.
Article in PloS one. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Impacts of visual impairment on pragmatic impairment: A systematic review and meta-analysis.PloS one · 2023Pooled it
- Utilization patterns of eye care services among women in outreach camps: A retrospective study from Nepal.Journal of public health research · 2026Article
- Causal associations between cognitive impairments and retinal diseases: A two-sample Mendelian randomization study.The Journal of international medical research · 2025Article
- Recovery of the Pupillary Response After Light Adaptation Is Slowed in Patients with Age-Related Macular Degeneration.Journal of eye movement research · 2025Article
- Patient-Reported Social Impact of Molecularly Confirmed Macular Dystrophies and Cone-Rod Dystrophies.Journal of clinical medicine · 2025Article
- ROQUS: a retinal OCT quality and usability score.Biomedical optics express · 2025Article
- Clinical and Biochemical Characterization of Specific GUCY2D Alleles Associated With a Rare Form of Night Blindness.Investigative ophthalmology & visual science · 2025Article
- Patient-Reported Social Impact of Molecularly Confirmed Retinitis Pigmentosa.Journal of clinical medicine · 2025Article
- The value of genetic testing in pediatric and adult ophthalmology.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2025Article
- Clinical and Socioeconomic Burden of Retinal Diseases: Can Biosimilars Add Value? A Narrative Review.Ophthalmology and therapy · 2025Review
- Anomaly Detection in Retinal OCT Images With Deep Learning-Based Knowledge Distillation.Translational vision science & technology · 2025Article
- Looking outside the box with a pathology aware AI approach for analyzing OCT retinal images in Stargardt disease.Scientific reports · 2025Article
- The incidence of visual impairment due to retinitis pigmentosa has declined in Finland over the last 40 years.Acta ophthalmologica · 2025Article
- Indications of the SERPINE 1 variant rs1799768's role in anti-VEGF therapy resistance in neovascular age-related macular degeneration.PloS one · 2025Article
- Article
- Association Between Visual Impairment and Daily Internet Use Among Older Japanese Individuals: Cross-Sectional Questionnaire Study.JMIR formative research · 2024Article
- Article
- Changing Trends in the Disease Burden of Cataract and Forecasted Trends in China and Globally from 1990 to 2030.Clinical epidemiology · 2023Article
- miR-140-5p and miR-140-3p: Key Actors in Aging-Related Diseases?International journal of molecular sciences · 2022Review
- Trends in Neonatal Ophthalmic Screening Methods.Diagnostics (Basel, Switzerland) · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the prevalence and causes of visual impairment and blindness in a Central European country. The findings may have implications for the planning of further research and development of therapies in order to prevent blindness.
settingDepartment of Ophthalmology, Medical University of Graz, Austria.
designRetrospective, epidemiological study.
methodsThe database of the Main Confederation of Austrian Social Insurances was searched for patients with visual impairment, legal blindness or deaf-blindness. This database gathers data from patients of all insurance providers in the country who receive care due to visual impairment and blindness. To determine the prevalence of these conditions, the number of all entries recorded in February 2019 was evaluated. Additionally, all new entries between (January 1st,) 2017, and (December 31st,) 2018, were analysed for distinct characteristics, such as sex, the cause of blindness/visual impairment, and age. Since health care allowances can provide a considerable source of income (459.90€-936.90€ per month), good coverage of practically all patients who are blind and visually impaired in the country can be assumed.
resultsOn February 2nd, 2019, 17,730 patients with visual impairments, blindness or deaf-blindness were registered in Austria, resulting in a prevalence of these diagnoses of 0.2% in the country. During the observational period from 2017 to 2018, 4040 persons met the inclusion criteria. Of these, 2877 were female (65.3%), and 1527 were male (34.7%). The mean age was 75.7 ± 18.0 years (median 82). Most patients (n = 3675, 83.4%) were of retirement age, while 729 (16.6%) were working-age adults or minors. In total, an incidence of 25.0 (95% confidence limit (CL) 24.3-25.8) per 100,000 person-years was observed from 2017 to 2018. A higher incidence was observed for females (32.2, 95% CL 31.0-33.3) than for males (17.7, 95% CL 16.8-18.5). Incidences where higher for males in lower age groups (e.g. 10-14 years: rate ratio RR = 2.7, 95% CL 1.1-6.8), and higher for females in higher age groups (e.g. 70-74 years: RR = 0.6, 95% CL 0.5-0.8). In total, the most frequent diagnoses were macular degeneration (1075 persons, 24.4%), other retinal disorders (493 persons, 11.2%) and inherited retinal and choroidal diseases (IRDs) (186 persons, 4.2%). Persons with IRDs were significantly younger compared to persons with macular degeneration or retinal disorders (IRDs: median 57, range 2-96 vs 83, 5-98 and 82, 1-98 years, p<0.001). For persons of retirement age, macular degeneration, other retinal disorders and glaucoma were the three most frequent diagnoses. In contrast, among working-aged adults and children, IRDs were the leading cause of visual impairment and blindness (103 persons, 14.1%).
conclusionThese data show that IRDs are the leading cause of blindness and visual impairment in working-aged persons and children in Austria. Thus, these findings suggest to draw attention to enhance further research in the fields of emerging therapies for IRDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.